## UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder

[Read More](/content/newsroom/press-releases/article/ucb-announces-positive-results-from-gemz-phase-3-study-of-fenfluramine-in-cdkl5-deficiency-disorder/index.html)

### UCB to present new data from its neurology portfolio at the 11th European Academy of Neurology (EAN) Congress 2025

[Read More](/content/newsroom/press-releases/article/ucb-to-present-new-data-from-its-neurology-portfolio-at-the-11th-european-academy-of-neurology-ean-congress-2025/index.html)

### Transparency notification FMR LLC

[Read More](/content/newsroom/press-releases/article/transparency-notification-fmr-llc-12/index.html)

### UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

[Read More](/content/newsroom/press-releases/article/ucb-announces-major-us-investment-to-expand-biologics-manufacturing-capacity/index.html)

### Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activities

[Read More](/content/newsroom/press-releases/article/dapirolizumab-pegol-phase-3-data-in-sle-presented-at-the-annual-european-congress-of-rheumatology-eular-show-improvement-in-fatigue-and-reduction-in-disease-activit/index.html)

### BIMZELX®▼(bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis

[Read More](/content/newsroom/press-releases/article/bimzelxrvbimekizumab-three-year-data-at-eular-2025-showed-lasting-efficacy-and-control-of-inflammation-in-psoriatic-arthritis-and-axial-spondyloarthritis/index.html)